You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 4,456,590

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,456,590

Title:	Heat treatment of lyophilized blood clotting factor VIII concentrate
Abstract:	A method for treating blood products to eliminate hepatitis virus present therein is disclosed. Blood products treated according to the method are first lyophilized and then subjected to heat for a period of time sufficient to inactivate the hepatitis virus. At the conclusion of the heating step the blood product can be reconstituted using sterile water or a like diluent. No adverse effects on blood product activity following treatment have been observed. The method has special applicability to blood plasma fractions such as Factor VIII, Factor IX and fibrinogen.
Inventor(s):	Rubinstein; Alan (Houston, TX)
Assignee:	Cedars Sinai Medical Center (Los Angeles, CA)
Application Number:	06/377,863
Patent Claims:	1. A method for treating blood clotting Factor VIII concentrate in order to minimize the effect of any hepatitis virus present in the blood clotting Factor VIII concentrate, said method comprising the steps of: lyophilizing the blood clotting Factor VIII concentrate, followed by; heating the lyophilized blood clotting Factor VIII concentrate at a predetermined temperature of at least about 60.degree. C. for a period of time sufficient to render hepatitis virus present in the blood clotting Factor VIII concentrate non-infectious, said heating generally decreasing as said predetermined temperature is increased. 2. The method claimed in claim 1 wherein said predetermined temperature is between about 60.degree. C. and about 100.degree. C. 3. The method claimed in claim 1 wherein said predetermined temperature is between about 60.degree. C. and about 125.degree. C. 4. The method claimed in claim 1 further comprising: adding sterile water to the lyophilized blood Factor VIII concentrate following completion of said heating step until solubilization of the lyophilized blood clotting Factor VIII concentrate is achieved.

Details for Patent 4,456,590

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2001-06-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.